Hypothesis

Age‑related decline of Lactonifactor longoviformis reduces equol production from dietary daidzein, diminishing ERβ‑mediated anti‑inflammatory signaling and accelerating inflammaging.

Mechanistic rationale

While L. longoviformis is known for lignan dehydrogenation, its genome harbors flavin‑dependent reductase domains homologous to those in validated equol‑producing strains (e.g., Slackia isoflavoniconvertens). Age‑associated shifts in bile acid pools—particularly increased secondary bile acids such as deoxycholic acid—have been shown to suppress Clostridiaceae metabolic activity Bile acid inhibition. We hypothesize that these bile acid changes selectively inhibit the cryptic daidzein‑reducing pathway in L. longoviformis, lowering equol synthesis in older hosts.

Equol acts as a selective estrogen receptor β (ERβ) agonist, dampening NF‑κB driven cytokine production ERβ anti‑inflammatory. Reduced equol therefore removes a microbial checkpoint on intestinal and systemic inflammation, contributing to the well‑documented decline in tryptophan‑indole metabolism Tryptophan decline and the rise of inflammaging observed after age 34‑54.

Testable predictions

1. Abundance correlation – Quantitative PCR targeting the L. longoviformis 16S rRNA gene will show a significant negative correlation with host age (r < ‑0.4, p < 0.01) across cohorts aged 20‑80.
2. Activity assay – Fecal slurries from young donors will convert daidzein to equol anaerobically at rates ≥2‑fold higher than those from age‑matched older donors after controlling for total bacterial load.
3. Bile acid modulation – Adding physiological concentrations of deoxycholic acid to in vitro cultures will decrease L. longoviformis‑mediated equol production by ≥50 % without affecting overall growth, indicating direct enzymatic inhibition.
4. Host phenotype – Elderly participants with low fecal equol (<5 nmol/g) will exhibit higher plasma IL‑6 and TNF‑α levels and poorer performance on cognitive endurance tests compared with high‑equol peers, even after adjusting for soy intake.
5. Intervention rescue – Targeted supplementation with a bile‑acid sequestrant (e.g., cholestyramine) combined with a defined L. longoviformis‑rich probiotic will restore equol production to youthful levels in a randomized, double‑blind trial (n = 60 per arm) and concomitantly reduce inflammatory biomarkers.

Falsifiability

If any of the following observations hold, the hypothesis is refuted:

• No age‑related decline in L. longoviformis abundance or equol‑producing activity is detected despite rigorous quantification.
• Manipulating bile acid concentrations does not alter equol output from L. longoviformis cultures.
• Elderly low‑equol individuals do not show elevated inflammatory markers relative to high‑equol counterparts when soy intake is equal.
• Probiotic‑sequestrant intervention fails to raise equol levels or improve inflammatory outcomes.

Broader implications

Confirming this link would position L. longoviformis as a keystone modulator of the gut‑estrogen axis, opening precision‑microbiome strategies to mitigate age‑related inflammation, bone loss, cardiovascular risk, and cognitive decline. It also explains why broad‑spectrum fiber or FMT approaches have yielded inconsistent effects on equol‑dependent health outcomes—they may not specifically resuscitate the bile‑acid‑sensitive L. longoviformis niche.